Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10156632 | 0.86 | ALDH1A1 (0.37) | FOLH1HTR7CHRM1TBXA2RADRA1A | |
| SCHEMBL21791312 | 0.84 | ELANE (0.37) | FOLH1HTR7CHRM1TBXA2RADRA1A | |
| SCHEMBL15413215 | 0.83 | FOLH1 (0.36) | FOLH1HTR7CHRM1TBXA2RADRA1A | |
| SCHEMBL26048460 | 0.83 | KDM4E (0.36) | FOLH1HTR7CHRM1TBXA2RADRA1A | |
| SCHEMBL22336901 | 0.83 | FOLH1 (0.33) | FOLH1HTR7CHRM1TBXA2RADRA1A | |
| SCHEMBL4479703 | 0.83 | FOLH1 (0.38) | FOLH1HTR7CHRM1TBXA2RADRA1A | |
| SCHEMBL10193622 | 0.83 | ALDH1A1 (0.36) | FOLH1HTR7CHRM1TBXA2RADRA1A | |
| SCHEMBL15413216 | 0.81 | FOLH1 (0.38) | FOLH1HTR7CHRM1TBXA2RADRA1A | |
| SCHEMBL2737085 | 0.81 | ALDH1A1 (0.38) | FOLH1HTR7CHRM1TBXA2RADRA1A | |
| SCHEMBL24326019 | 0.81 | FOLH1 (0.33) | FOLH1HTR7CHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303599-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303599-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20220119426-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| WO-2018081513-A1 | PRODRUGS OF KALLIKREIN INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119426-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | PNP, TYMP, NME2 | FOLH1 645/4885HTR7 4039/4885CHRM1 4247/4885 |
| US-20230303599-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | PNP, TYMP, NME2 | FOLH1 645/4885HTR7 4039/4885CHRM1 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.